Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development
Open Access
- 17 November 2022
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (11) , 2495
Abstract
Dry powder inhalers (DPIs) are drug–device combination products where the complexity of the formulation, its interaction with the device, and input from users play important roles in the drug delivery. As the landscape of DPI products advances with new powder formulations and novel device designs, understanding how these advancements impact performance can aid in developing generics that are therapeutically equivalent to the reference listed drug (RLD) products. This review details the current understanding of the formulation and device related principles driving DPI performance, past and present research efforts to characterize these performance factors, and the implications that advances in formulation and device design may present for evaluating bioequivalence (BE) for generic development.Keywords
This publication has 111 references indexed in Scilit:
- Effect of Device Design on the In Vitro Performance and Comparability for Capsule-Based Dry Powder InhalersThe AAPS Journal, 2012
- In silico models of aerosol delivery to the respiratory tract — Development and applicationsAdvanced Drug Delivery Reviews, 2012
- Tobramycin administered by the TOBI® Podhaler® for persons with cystic fibrosis: a reviewMedical Devices: Evidence and Research, 2011
- Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ TechnologyJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2011
- Aerosol drug delivery: developments in device design and clinical useThe Lancet, 2011
- In Vivo–In Vitro Correlations: Predicting Pulmonary Drug Deposition from Pharmaceutical AerosolsJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- Formulation strategy and use of excipients in pulmonary drug deliveryInternational Journal of Pharmaceutics, 2010
- In Vitro Considerations to Support Bioequivalence of Locally Acting Drugs in Dry Powder Inhalers for Lung DiseasesThe AAPS Journal, 2009
- The DiskusTM: a review of its position among dry powder inhaler devicesInternational Journal Of Clinical Practice, 2007
- Aerodynamic properties of elongated particles of cromoglycic acidJournal of Aerosol Science, 1989